Knowthestock.com
CPRX - Catalyst Pharmaceuticals Inc

Buy

Strong Growth and StableStock Price Attractive
WeakStrong
WeakStrong

89%

based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 29.97%
Operating Income Growth is 195.38%
Net Income Growth is 203.07%
Earnings Per Share (EPS) Growth is 190.74%
Net Margin is 36.91%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 6.14
Debt Ratio is 0.13
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is STRONG
Cash from Operations Growth is 63.91%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Catalyst Pharmaceuticals Inc (CPRX) - https://catalystpharma.com/
catalyst pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including lambert-eaton myasthenic syndrome (lems), congenital myasthenic syndromes (cms), infantile spasms, and tourette's disorder. catalyst's lead candidate, firdapse® for the treatment of lems, has completed testing in a global, multi-center, double-blinded randomized pivotal phase 3 trial resulting in positive top-line data and catalyst has recently filed an nda for this product seeking approval for its use as a treatment of lems and cms. firdapse® for the treatment of lems has received breakthrough therapy designation from the u.s. food and drug administration (fda) and orphan drug designation for lems and cms. firdapse® is the first and only european approved drug for symptomatic treatment in adults with lems. catalyst is also developing cpp-115 to treat infantile spasms, epilepsy and other neurological conditions asso
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Patrick McEnany
Employees - 71
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.